About velaglucerase alfa
Enzyme replacement therapy
Used for
- Long-term treatment of type 1 Gaucher disease
- Treatment of type 3 Gaucher disease in adults and children
Usual adult dose
60 units/kg by intravenous infusion every other week; dose may be adjusted.
Usual dose in children
60 units/kg by intravenous infusion every other week; for type 1 or type 3 Gaucher disease.
Common side effects
- Infusion reactions, including headache, dizziness, or flushing
- Abdominal pain, nausea, or fatigue
- Rash or itching
- Antibodies to the medicine may develop
Important warnings
- Serious allergic reactions, including anaphylaxis, can occur.
- Infusion reactions may require slowing or stopping the infusion.
- Use caution in people with a history of allergic reactions to the medicine.
- Dose changes should be guided by clinical response.
Pregnancy
Human pregnancy data are limited; use only when clearly needed after weighing potential benefits and risks.
Breastfeeding
It is unknown whether velaglucerase alfa passes into breast milk; consider benefits and potential risks.
Interactions
- No formal interaction studies have been conducted.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.